1,1-Dimethylbiguanide, Hydrochloride (Metformin) is a biguanide antihyperglycemic agent. Through glucose clamp investigation in rats 1,1-Dimethylbiguanide, Hydrochloride has been shown to lower blood glucose levels through improved glucose tolerance without stimulating insulin secretion, promoting weight gain or causing hypoglycemia. The biguanide reduces the diabetic complications on the cardiovascular system and increases insulin sensitivity. The compound has been shown not to change the synthesis of either GLUT4 or GLUT1 but does stimulate the transport of GLUT1 to the plasma membrane as seen in skeletal muscles. The compound has also been observed to improve peripheral arterials through selective reduction of PAI-1 (plasminogen activator inhibitor). In Xenopus oocytes the compound has been documented to act by increasing intercellular calcium concentration in addition to elevating receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate. 1,1-Dimethylbiguanide, Hydrochloride has demonstrated the ability to induce fatty acid oxidation and to stimulate AMP-activated protein kinase (AMPK) leading to the reduction in acetyl-CoA carboxylase activity. In brown adipocytes 1,1-Dimethylbiguanide, Hydrochloride has been observed to inhibit leptin secretion via a mitogen-activated protein kinase signalling pathway.
1. Vague, P.,et al. 1987. Thromb. Haemost. 57: 326-328. PMID: 3310318
2. Rossetti, L., et al. 1990. Metab. Clin. Exp. 39: 425-435. PMID: 2157941
3. Stith, B.J., et al. 1996. Endocrinology. 137: 2990-2999. PMID: 8770923
4. Lin, H.Z., et al. 2000. Nat. Med. 6: 998-1003. PMID: 10973319
5. Zhou, G., et al. 2001. J. Clin. Invest. 108: 1167-1174. PMID: 11602624
6. Cleasby, M.E., et al. 2004. Diabetes. 53: 3258-3266. PMID: 15561958
7. Klein, J., et al. 2004. J. Endocrinol. 183: 299-307. PMID: 15531718
8. Mohiuddin, M., et al. 2009. Pak. J. Biol. Sci. 12: 734-737. PMID: 19634481
See how others have used 1,1-Dimethylbiguanide, Hydrochloride. Click on the entry to view the PubMed entry .
PMID: # 28243322
García-Castillo, V. et al. 2017. Targeting Metabolic Remodeling in Triple Negative Breast Cancer in a Murine Model. J Cancer. 8: 178-189.
PMID: # 26771051
Kinsky, OR. et al. 2016. Metformin Scavenges Methylglyoxal To Form a Novel Imidazolinone Metabolite in Humans. Chemical research in toxicology.
PMID: # 11994296
Fryer, LG. et al. 2002. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem.. 277: 25226-25232.
PMID: # 11602624
Zhou, G. et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest.. 108: 1167-1174.
PMID: # 9428832
Garber, AJ. et al. 1997. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med.. 103: 491-497.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2017 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.